I-AASraw ivelisa i-NMN kunye ne-NRC powders ngobuninzi!

I-Sunitinib Malate

Akukho kalo Udidi:

I-Sunitinib inqanda umqondiso weselfowuni ngokujolisa kwii-receptor ezininzi ze-tyrosine kinases (i-RTKs) ezibandakanya zonke ii-receptors ze-platelet-derived ukukhula factor (PDGF-Rs) kunye ne-vascular endothelial factor factor receptors (VEGFRs), ezidlala indima kuzo zombini i-tumor angiogenesis kunye ne-tumor cell ukwanda.

Ingcaciso yeMveliso

Iimpawu ezisisisekocs

Igama lemveliso I-Sunitinib Malate powder
Inani leCAS 341031-54-7
I-Molecular Formula C22H27FN4O2
Ubunzima beMolar 398.474
Iintetho ezifanayo 557795-19-4;

Ngobuqhetseba;

I-Sunitinib i-malate powder;

I-SU11248.

Kubonakala Powder
Ukugcina nokuPhatha Yigcine kubushushu begumbi kwaye kude nobushushu obuninzi kunye nokufuma.

 

I-Sunitinib Malate powder Inkcazo

I-Sunitinib (ithengiswa njenge-Sutent yi-Pfizer, kwaye ngaphambili ibisaziwa njenge-SU11248) sisilumko somlomo, esincinci, esine-receptor tyrosine kinase (RTK) eyaye yamkelwa yi-FDA kunyango lwe-renal cell carcinoma (RCC) kunye ne-imatinib Isisu esomeleleyo esiswini esomeleleyo (GIST) nge-26 kaJanuwari ka-2006.

 

I-Sunitinib Malate powder Indlela yokusebenza

I-Sunitinib inqanda umqondiso weselfowuni ngokujolisa kwii-receptor ezininzi ze-tyrosine kinases (RTKs).

Oku kubandakanya zonke ii-receptors zeplatelet-derived growth factor (PDGF-Rs) kunye ne-vascular endothelial growth factor receptors (VEGFRs), ezidlala indima kuzo zombini i-tumor angiogenesis kunye ne-tumor cell proliferation. Ukuthintelwa ngaxeshanye kwezi njongo ke kunciphisa i-tumor vascularization kwaye kubangele umhlaza weeseli apoptosis kwaye ke oko kubangele ukuncipha kwethumba.

I-Sunitinib ikwathintela i-CD117 (c-KIT), [2] i-receptor tyrosine kinase ethi (xa yenziwe ngokungalunganga ngenguquko) iqhube uninzi lwesisu samathumbu esibeleko. Kwi-c-KIT ebenza ukuba banganyangeki kwi-imatinib, okanye abo bangakwaziyo ukulinyamezela ichiza.

 

I-Sunitinib Malate powder Isicelo

 Ithumba lesisu esiswini

Njenge-RCC, i-GIST ayiphenduli ngokubanzi kwi-chemotherapy esemgangathweni okanye kwimitha. I-Imatinib yayiyi-arhente yokuqala yomhlaza eqinisekiswe ukuba iyasebenza kwi-GIST ye-metastatic kwaye yamela ukukhula okukhulu kunyango lwesi sifo sinqabile kodwa sinzima.

 

 Meningioma

I-Sunitinib ifundelwa unyango lwe-meningioma enxulunyaniswa ne-neurofibromatosis.

 

 Amathumba epancreatic neuroendocrine

Ngo-Novemba ngo-2010, uSutent ufumene imvume kwiKhomishini yaseYurophu yokunyanga 'amathumba angenakuphikiswa okanye e-metastatic, ahluke kakuhle kwi-pancreatic neuroendocrine tumors ngokuqhubela phambili kwesifo kubantu abadala'.

 

 I-renal cell carcinoma

I-Sunitinib yamkelwe kunyango lwe-metastatic RCC. Olunye ukhetho lwezonyango kolu seto yi-pazopanib (Votrient), sorafenib (Nexavar), temsirolimus (Torisel), interleukin-2 (Proleukin), everolimus (Afinitor), bevacizumab (Avastin), kunye ne-aldesleukin.

 

I-Sunitinib Malate powder Iziphumo ebezingalindelekanga kunye nesilumkiso

Iziganeko ezimbi zeSunitinib zithathwa njengezilawulwayo kunye neziganeko ezimbi ezimbi ezisezantsi.

Ezona ziganeko zichaseneyo zixhomekeke kunyango lwe-sunitinib kukudinwa, urhudo, isicaphucaphu, i-anorexia, uxinzelelo lwegazi, umbala omthubi, ulusu lwenyawo kunye nokuphendula kwesikhumba. Kwisifundo esilawulwa yi-placebo seSigaba III se-GIST, izehlo ezichaseneyo ezenzeka rhoqo nge-sunitinib kune-placebo ibandakanya urhudo, i-anorexia, ibala lolusu, i-mucositis / stomatitis, i-asthenia, i-flavour eguqulweyo kunye nokuqhina.

Ukuncitshiswa kwethamo kwakufuneka kwi-50% yezigulana ezifundwe kwi-RCC ukulungiselela ukulawula iityhefu ezibalulekileyo zeli arhente.

Imicimbi emibi (yebanga lesi-3 okanye lesi-4) yeziganeko ezigwenxa zenzeka kwi-10% yezigulana kwaye zibandakanya uxinzelelo lwegazi, ukudinwa, i-asthenia, isifo sorhudo, kunye ne-chemotherapy-induction acral erythema. Ukungaqheleki kwelebhu enxulunyaniswa nonyango lwe-sunitinib kubandakanya lipase, amylase, neutrophils, lymphocytes, kunye neeplatelets. I-Hypothyroidism kunye ne-erythrocytosis eguqukayo ikwayanyaniswa ne-sunitinib.

 

isingqiniso

[1] Ulawulo lwezoKutya noLawulo lweziyobisi (2006). "I-FDA iyalwamkela unyango olutsha lomhlaza wamathumbu kunye nezintso".

[2] UHartmann JT, Kanz L (Novemba 2008). "I-Sunitinib kunye nokuchithwa kweenwele ngamaxesha athile ngenxa ye-c-KIT inhibition yethutyana". IArch Dermatol. I-144 (11): 1525-6. ikhonkco: 10.1001 / archderm.144.11.1525. I-PMID 19015436. Kugciniwe ukusuka kwinto yokuqala ngo-2011-07-25.

[3] Quek R, George S (ngoFebruwari 2009). "Isisu somzimba esiswini: isishwankathelo seklinikhi". IHematol. Ifayile yeOncol. Iklinikhi. EMantla Am. 23 (1): 69-78, viii. ikhonkco: 10.1016 / j.hoc.2008.11.006. IINKCUKACHA:

[4] Blay JY, Reichardt P (Juni 2009). "Isisu esibuhlungu esiswini esiseYurophu: uphononongo lweengcebiso zonyango ezihlaziyiweyo" Ingcali ngeRev Anticancer Ther. 9 (6): 831-8. ikhonkco: 10.1586 / era.09.34. I-PMID 19496720. I-S2CID 23601578.

[5] UGan HK, uSeruga B, uKnox JJ (ngoJuni 2009). "I-Sunitinib kwizilonda eziqinileyo". Ingcali Opin Phanda iziyobisi. 18 (6): 821-34. ikhonkco: 10.1517 / 13543780902980171. IINKCUKACHA:

[6] "Ukumisela ulwazi lweSutent (sunitinib malate powder)". IPfizer, Inc, eNew York NY.


  • Gefitinibfree Funda ngokugqithisileyo
  • I-AZD-9291free Funda ngokugqithisileyo
  • Ibrutinibfree Funda ngokugqithisileyo